Clinical Report: Understanding the BALANCE Model for GLP-1 Medications
Overview
Update to reflect that the BALANCE Model will not be implemented in Medicare Part D in 2027.
Background
GLP-1 medications have gained popularity for treating conditions like type 2 diabetes and obesity, yet coverage remains limited, particularly for obesity treatment under Medicare and Medicaid. Current laws restrict Medicare from covering obesity drugs, impacting access for many low-income beneficiaries. The BALANCE Model represents a significant policy shift towards recognizing obesity as a disease and improving treatment access.
Data Highlights
Revise to include the latest statistics and spending figures, considering the Bridge program.
Key Findings
Incorporate the extension of the GLP-1 Bridge program and its effects on coverage.
Clinical Implications
Highlight the need for providers to stay informed about temporary coverage changes.
Conclusion
The BALANCE Model represents a critical step towards improving access to GLP-1 medications for obesity treatment in Medicare and Medicaid, reflecting a broader recognition of obesity as a significant health concern.
